Teva Pharma (NYSE: TEVA) reported Q1 EPS of $1.36, $0.11 better than the analyst estimate of $1.25. Revenue for the quarter came in at $5 billion versus the consensus estimate of $4.84 billion.

For earnings history and earnings-related data on Teva Pharma (TEVA) click here.